HOME >> BIOLOGY >> NEWS
Other highlights in the July 7 JNCI

Study Evaluates Design of Phase I Trials for Targeted Cancer Drugs

One purpose of a phase I clinical trial of a new cytotoxic drug is to determine the side effects associated with increasing drug dose, i.e., determine the dose that produces the maximum effect at which the toxicity can still be tolerated. New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to this paradigm because they can achieve their maximum effect at levels lower than the maximum tolerated dose.

In a new study, Wendy R. Parulekar, M.D., and Elizabeth A. Eisenhauer, M.D., of Queen's University in Kingston, Ontario, reviewed endpoints used in 60 published phase I studies of targeted, non-cytotoxic anticancer agents. They found that the majority of studies used the traditional endpoint of toxicity to determine the recommended dose for the phase II trials. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection.

The authors conclude that although phase I studies of targeted anticancer agents in general continue to use traditional endpoints for selection of the recommended phase II dose, suitable molecular measures of drug effect and the means to incorporate them in the early drug development process are needed to optimize dose selection and drug development strategies.

In an editorial, Edward L. Korn, Ph.D., of the National Cancer Institute, discusses the assumptions and considerations required for choosing an endpoint in a phase I trial of a cytotoxic agent, and the challenges in using nontraditional endpoints for the dose selection of targeted, non-cytotoxic agents.

Contact: Wendy Parulekar, Queen's University, wparulekar@ctg.queensu.ca


Possible T
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jul-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the June 16 JNCI
5. Other Highlights in the June 2 JNCI
6. Other highlights in the May 19 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... ... September 09, 2019 , ... Greenberg Traurig, LLP attorneys Stephen ... will speak at DeviceTalks Minnesota, Sept. 9-10, at the Hyatt Regency, Minneapolis. Greenberg Traurig ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference ...
(Date:9/8/2019)... ... September 06, 2019 , ... ... and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, ... cord (hUC) MSC paired cell and media system designed for product development. ...
(Date:8/31/2019)... FRANCISCO (PRWEB) , ... August 30, 2019 , ... ... startup making beautiful, science-backed conception essentials. Natalist empowers consumers in the preconception period ... of essentials to support people each month that are trying to get pregnant. ...
Breaking Biology News(10 mins):
(Date:8/29/2019)... ROCHESTER, N.Y. (PRWEB) , ... August 29, 2019 ... ... within a chronic disease affecting grapevines, a feat they hope will ultimately help ... products. , Researchers including several Rochester Institute of Technology faculty and alumni sequenced ...
(Date:8/27/2019)... ... August 27, 2019 , ... ... to announce it has promoted Consulting Engineer, Robert Battista, to Senior Consulting engineer. ... responsibility of onboarding and mentoring new engineers as well as the creation of ...
(Date:8/15/2019)... ... August 15, 2019 , ... PathSensors announced today ... a member of the Institute of Food Technologists (IFT) Board of Directors, Illinois ... Joint Institute for Food Safety and Applied Nutrition (JIFSAN) Advisory Council and the ...
(Date:8/7/2019)... ... August 07, 2019 , ... Locus Agricultural Solutions (Locus AG) reports record ... (soil “probiotics”), including Rhizolizer ® , which is pulling up to 121% more ... has offered to date. Results from the treatment of almonds, cherries, turf/sod, grapes and ...
Breaking Biology Technology:
Cached News: